WO2016112078A3 - Anti-phf-tau antibodies and their uses - Google Patents
Anti-phf-tau antibodies and their uses Download PDFInfo
- Publication number
- WO2016112078A3 WO2016112078A3 PCT/US2016/012293 US2016012293W WO2016112078A3 WO 2016112078 A3 WO2016112078 A3 WO 2016112078A3 US 2016012293 W US2016012293 W US 2016012293W WO 2016112078 A3 WO2016112078 A3 WO 2016112078A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phf
- tau
- tau antibodies
- isolated antibody
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
The present invention relates to anti- PHF-tau antibodies and methods of making and using them. One embodiment of the invention is an isolated antibody that binds PHF-tau comprising an antigen-binding site of a heavy chain variable region (VH) of SEQ ID NOs: 20, 22 or 23. Another embodiment of the invention is an isolated antibody that binds PHF-tau comprising certain heavy and light chain complementarity determining regions or heavy chain and light chain variable regions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101031P | 2015-01-08 | 2015-01-08 | |
US62/101,031 | 2015-01-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016112078A2 WO2016112078A2 (en) | 2016-07-14 |
WO2016112078A3 true WO2016112078A3 (en) | 2016-09-01 |
Family
ID=56356570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/012293 WO2016112078A2 (en) | 2015-01-08 | 2016-01-06 | Anti-phf-tau antibodies and their uses |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016112078A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
JOP20180014A1 (en) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
BR112020007536A2 (en) | 2017-10-16 | 2020-09-29 | Eisai R&D Management Co., Ltd. | anti-tau antibodies and their uses |
TW201946654A (en) * | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | Anti-PHF-Tau antibodies and uses thereof |
WO2020120644A1 (en) * | 2018-12-13 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162336A1 (en) * | 1991-12-06 | 2009-06-25 | Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. | Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease |
WO2013096380A2 (en) * | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
-
2016
- 2016-01-06 WO PCT/US2016/012293 patent/WO2016112078A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162336A1 (en) * | 1991-12-06 | 2009-06-25 | Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. | Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease |
WO2013096380A2 (en) * | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
Non-Patent Citations (4)
Title |
---|
"MAPT/PHF-tau Antibody, Rabbit PAb (Cat # 10058-RP01", 8 June 2012 (2012-06-08), pages 1 - 2., Retrieved from the Internet <URL:www.sinobiologicalcdn.com/upload/MSDS/10058-RP01.pdf> [retrieved on 20160411] * |
AUGUSTINACK ET AL.: "Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease", ACTA NEUROPATHOL., vol. 103, January 2002 (2002-01-01), pages 26 - 35, XP002625811, doi:10.1007/S004010100423 * |
D'ABRAMO ET AL.: "Tau passive immunotherapy in mutant P301 L mice: antibody affinity versus specificity", PLOS ONE., vol. 8, no. e62402., 29 April 2013 (2013-04-29), pages 1 - 10 * |
LICHTENBERG-KRAAG ET AL.: "Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau", PROC NATL ACAD SCI USA, vol. 89, 15 June 1992 (1992-06-15), pages 5384 - 5388, XP002226003, doi:10.1073/pnas.89.12.5384 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016112078A2 (en) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016112078A3 (en) | Anti-phf-tau antibodies and their uses | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
WO2016014688A3 (en) | Anti-pd-1 antibodies | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
CR20170026A (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
EP3575322A4 (en) | Anti-pd-1 monoclonal antibody, and preparation method therefor and application thereof | |
ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
NZ728749A (en) | Anti-pd-l1 antibodies | |
WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EP3532489A4 (en) | Neutralizing anti-tl1a monoclonal antibodies | |
MX2016008794A (en) | E. coli specific antibody sequences. | |
EA201990672A1 (en) | ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS | |
WO2016205427A3 (en) | Binding proteins against vegf, pdgf, and/or their receptors | |
EP3487518A4 (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) | |
PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
AU2017255888A1 (en) | Humanized anti-BASIGIN antibodies and the use thereof | |
WO2017021539A3 (en) | Novel anti-human gpvi antibodies and uses thereof | |
WO2015189638A3 (en) | Autoantibodies associated with rheumatoid arthritis | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
EP3846850A4 (en) | Humanized anti-c5 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16735340 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16735340 Country of ref document: EP Kind code of ref document: A2 |